Physician profile
Sameer Waheed
NPI 1225311095
$3,549.90
in general payments reported to CMS, 2019-2025
25 companies · $396 in 2025
The $396 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $220 · 2020: $119 · 2021: $337 · 2022: $663 · 2023: $791 · 2024: $1,023 · 2025: $396.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,210.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,209.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $624.68 | 2022-2025 | Impella |
| E.R. Squibb & Sons, L.L.C. | $577.34 | 2022-2024 | Eliquis, Camzyos |
| Medtronic, INC. | $559.05 | 2021-2025 | Corevalve Evolut R |
| Boston Scientific Corporation | $420.75 | 2021-2025 | Watchman Flx, Watchman, Watchman Access System |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $165.66 | 2022-2025 | Lifevest |
| Lantheus Medical Imaging, INC. | $134.18 | 2019-2020 | |
| Pfizer INC. | $114.57 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $104.64 | 2021-2025 | |
| Medtronic Vascular, INC. | $102.01 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $97.51 | 2019-2024 | Farxiga |
| Philips North America LLC | $68.04 | 2021-2023 | |
| Abbott Laboratories | $67.43 | 2021 | |
| Asahi Intecc USA, INC. | $65.82 | 2021 | |
| Janssen Pharmaceuticals, INC | $65.24 | 2022-2023 | Xarelto |
| Baxter Healthcare | $63.83 | 2023-2025 | Hillrom - Carnation Ambulatory Monitor |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $52.31 | 2022-2024 | Verquvo |
| Atricure, INC. | $49.65 | 2023 | |
| Amgen INC. | $44.25 | 2022-2023 | Repatha |
| Kiniksa Pharmaceuticals International, Plc | $34.98 | 2024 | Arcalyst |
| Cardiovascular Systems INC. | $32.30 | 2022 | |
| Cardiva Medical, INC. | $27.14 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $24.33 | 2025 | |
| Esperion Therapeutics, INC. | $20.48 | 2024 | Nexletol |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.56 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $14.15 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sameer Waheed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.